The packed PD-(L)1 game just got another player — a low-profile biosimilars company looking to branch out with a $150M cash pact
After the majors lined up their PD-(L)1s, a low-profile biosimilars company has stepped up with the latest partnership as the next wave of checkpoints is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
